Psychiatry
Your trial CORE-powered
Sleep
Neurodegenerative Diseases
Pain
Sleep
Experience with sleep centers in 25 countries
IQVIA has experience in narcolepsy, idiopathic hypersomnia, insomnia, obstructive sleep apnea, excessive sleep disorder with a focus on integrating connected devices to ensure meaningful trial outcomes.
THE PROOF
Since 2010, IQVIA has delivered 21 trials for numerous sleep indications
Neurodegenerative Diseases
Driving success by identifying the right patients, in the right place, at the right time
With unparalleled NDD experience, IQVIA delivers trials in ALS*, Parkinson’s disease, Alzheimer’s disease and other dementias. We implement data-driven recruitment and site identification by leveraging our global competitive landscape knowledge and vast data.
65 Alzheimer’s disease trials involving 27,000 patients enrolled in 40+ countries
THE PROOF
*Including two of the largest global phase III ALS trials ever conducted
Pain
Offering deep understanding of – and solutions for – diverse pain indications
We tailor solutions for acute and chronic pain, optimize protocols, and implement novel trial designs globally with traditional and decentralized trials, connected devices, ePRO, and eCOA. IQVIA’s experience includes migraine, central and peripheral neuropathic pain disorders.
THE PROOF
Neuromuscular Diseases
Combining therapeutic and operational expertise to support unique therapeutic approaches
IQVIA provides expertise in rare diseases, pediatrics, and cell and gene therapy. We deliver patient-centric trial solutions by leveraging partnerships with influential patient advocacy groups and site networks, and we create and maintain patient registries.
IQVIA’s unrivaled team of experts is working alongside our customers to deliver new, better medicines to patients faster.
Click each area to learn more
Neuromuscular
Diseases
Neurology
Neurology
Experience delivering decentralized and traditional clinical trials across neurology indications
Our experience spans all multiple sclerosis forms, rare and pediatric epilepsies and niche rare diseases. We have extensive expertise in neuroradiology and clinical outcomes scales and experience with wearables and digital biomarkers.
Phase I-IV multiple sclerosis studies delivered since 2010:
THE PROOF
Intelligently connect your CNS trials
Psychiatry
Driving success by enrolling the right patients and delivering reliable endpoint data
We maximize the value of psychiatric compounds and compress time-to-market through therapeutic knowledge, clinical delivery excellence and analytics. We ensure high-quality data and trial delivery by implementing safe, flexible processes and workstreams.
THE PROOF
Since 2010, IQVIA has supported 11 psychiatry drug approvals for adult and pediatric populations
17 ALS studies, enrolling approximately 3000 patients across 15+ countries
psychiatry approvals
since 2010
11
21
trials for Sleep
since 2010
Z
Z
Z
65
Alzheimer's disease trials since 2011
17
ALS studies
since 2010
69
Pain trials
40+
Compounds
18,200+
Patients
60+
Countries
94
Trials
36,800+
Patients recruited
Psychiatry
Sleep
Neurodegenerative Diseases
Pain
Neuromuscular
Diseases
Neurology
Neurology
Neuromuscular
Diseases
Pain
Neurodegenerative Diseases
Sleep
Psychiatry
CNS trials
Since 2010, IQVIA has delivered:
Tap each area to learn more
Through our CORE-powered approach to cardiovascular development, IQVIA can help you rethink old challenges and surround your trials with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring game-changing therapies to patients sooner.
Intelligently connect your CNS trials
< BACK
< BACK
< BACK
< BACK
< BACK
< BACK
CNS trials
CNS trials
CNS trials
CNS trials
CNS trials
